Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes

Lovshin, Julie A., Barnie, Annette, DeAlmeida, Ariana, Logan, Alexander, Zinman, Bernard, Drucker, Daniel J.·2015·Diabetes Care
DOI 10.2337/dc14-1958

Cited by (167)

Items 101–167 of 167

  1. Incretin and glucagon receptor polypharmacology in chronic kidney disease
    Brandon E. McFarlin, Kevin L. Duffin, Anish A. Konkar · 2024 · American Journal of Physiology-Endocrinology and Metabolism
  2. Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
    Masashi Hasebe, Chen‐Yang Su, Yamato Keidai, Hiroto Minamino, Daisuke Yabe, Nobuya Inagaki, Satoshi Yoshiji · 2025 · Diabetes Obesity and Metabolism
  3. Exploring the potential impact of GLP-1 receptor agonists in cancer therapy
    Baseer Aslam, Muhammad Daim Bin Zafar, Mah I Kan Changez, Muhammad ABDULLAH, Muhammad Safwan, Bisma QAMAR, Abdullah SHINWARI, Sanjana RAI · 2023 · Minerva Endocrinology
  4. Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis
    Fizza Iqbal, Muhammad Hamza Shuja, L. Azam, Marium Amjad, Kashish Zehra Manjee, Hurriyah Ramzan, Taha Sharif, Ayesha Shoaib, Amber Tahir, Satesh Kumar et al. · 2024 · Endocrine Practice
  5. New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy
    Aikaterini Damianaki, Erietta Polychronopoulou, Grégoire Wuerzner, Michel Burnier · 2021 · High Blood Pressure & Cardiovascular Prevention
  6. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
    Ronald Goldenberg, Murray J Berall, Christopher T. Chan, David Z.I. Cherney, Julie A. Lovshin, Philip A. McFarlane, Peter Alexander Senior, Subodh Verma, Jordan J. Weinstein · 2017 · Canadian Journal of Diabetes
  7. Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes
    HARPREET SINGH BAJAJ, Badr A. Aljabri, Subodh Verma · 2018 · Current Opinion in Cardiology
  8. Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
    Domenico Tricò, Anna Solini · 2021 · Advances in Chronic Kidney Disease
  9. Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice
    Stephanie E. Simonds, Jack T. Pryor, Frank H. Koegler, Alberte Silke Buch-Rasmussen, Lauren E. Kelly, Kevin L. Grove, Michael Alexander Cowley · 2019 · Diabetes
  10. Hematopoietic cell– versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice
    Elodie M. Varin, Antonio A. Hanson, Jacqueline Leah Beaudry, My-Anh Nguyen, Xiemin Cao, Laurie L. Baggio, Erin E. Mulvihill, Daniel J. Drucker · 2020 · JCI Insight
  11. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
    Keith C. Ferdinand, Julia P. Dunn, Claudia Nicolay, Flora Sam, Emily K. Blue, Hui Wang · 2023 · Cardiovascular Diabetology
  12. Combinatorial inhibition of Angiotensin converting enzyme, Neutral endopeptidase and Aminopeptidase N by N-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension
    Mysuru Natarajan Savitha, Kanve Nagaraj Suvilesh, Jalahalli Mariswamy Siddesha, Mallanayakanakatte D. Milan Gowda, Manisha Choudhury, Devadasan Velmurugan, Muddegowda Umashankara, Bannikuppe Sannanaik Vishwanath · 2019 · Peptides
  13. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
    Takeyuki Hiramatsu, Hiroki Ito, Shota Okumura, Yuko Asano, Daiki Iguchi, Shinji Furuta · 2020 · Diabetes and Vascular Disease Research
  14. Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study
    Takeyuki Hiramatsu, Akiko Ozeki, Hideaki Ishikawa, Shinji Furuta · 2017 · Drug Research
  15. Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
    Rodrigo O. Moreira, Cynthia Melissa Valério, Alexandre Hohl, Cristiane Moulin, Fábio Moura, Fábio Rogério Trujilho, Fernando Gerchman, Lívia L. Corrêa, Márcio C. Mancini, Maria Edna de Melo et al. · 2024 · Archives of Endocrinology and Metabolism
  16. Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
    Jean‐Philippe Krieger, Derek Daniels, Shin Jae Lee, Svetlana Mastitskaya, Wolfgang Langhans · 2024 · Comprehensive physiology
  17. Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis
    Pratyaksh K. Srivastava, Aruna D. Pradhan, Nancy R. Cook, Paul M. Ridker, Brendan M. Everett · 2017 · Journal of the American Heart Association
  18. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
    Saleh Fahad Alqifari, Omar Al Komi, Abdullah Esmail, Khadijeh Alkhawami, Shahd Yousri, Mohamad Ayham Muqresh, Nawwarah Alharbi, Abdullah Abdulaziz Abdulwahab Khojah, Ahmed Mohammed Aljabri, Abdulrahman Allahham et al. · 2024 · World Journal of Diabetes
  19. The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis
    Dimitrios Patoulias, Christodoulos E. Papadopoulos, Fotios Siskos, Konstantinos Stavropoulos, Michael N. Doumas · 2021 · Blood Pressure Monitoring
  20. Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes ( RENALIS ): A predefined substudy of a randomized, double‐blind trial
    Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens Juul Holst, A.H. Jan Danser, Jaap A. Joles, Daniël H. van Raalte · 2021 · Diabetes Obesity and Metabolism
  21. Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation
    Cen Yan, Xiaojuan Ma, Sin Man Lam, Yuejie Zhang, Yu Cao, Yuan Dong, Su Li, Guanghou Shui, Yingmei Feng · 2023 · Journal of Molecular Cell Biology
  22. Physiological adaptations following Roux-en-Y gastric bypass and the identification of targets for bariatric mimetic pharmacotherapy
    Neil Gerard Docherty, Carel Wynand le Roux · 2015 · Current Opinion in Pharmacology
  23. GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum
    V. Riehl-Tonn, Kyle D. Medak, C. Rampersad, Anne Macphee, T. Harrison · 2024 · Canadian Journal of Kidney Health and Disease
  24. Cardiovascular effects of tirzepatide
    Priya Sumithran, Anthony William Russell, Sophia Zoungas · 2025 · Journal of Endocrinology
  25. Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients
    Larry A. Weinrauch, George P Bayliss, Alissa R. Segal, Jiankang Liu, Eric Wisniewski, John A. D’Elia · 2016 · Journal of Clinical Hypertension
  26. Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study
    JOHAN H. JENDLE, Xin Lei Fang, Yang Cao, Leif Bojö, Bo Nilsson, Fredric Hedberg, Irene Santos‐Pardo, Thomas Nyström · 2018 · Journal of the American Society of Hypertension
  27. Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
    Di Zhao, Hui Liu, Pingshuan Dong · 2019 · Clinical and Experimental Hypertension
  28. Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines
    Michel Marre · 2020 · Diabetes Obesity and Metabolism
  29. Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study
    Sophie J. Clarke, Stephen Pettit, Joel P. Giblett, Tian Xiao Zhao, Anna C. Kydd, Nicolai J. Wewer Albrechtsen, Carolyn Fiona Deacon, Jayan K. Parameshwar, Stephen Paul Hoole · 2018 · Clinical Therapeutics
  30. Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment
    Vedrana Ivić, Milorad Zjalić, Senka Blažetić, Matija Fenrich, Irena Labak, Rudolf Scitovski, Kálmán Ferenc Szűcs, Eszter Ducza, Tamás Tábi, Fruzsina Bagaméry et al. · 2023 · Frontiers in Endocrinology
  31. The Differences of Mechanisms in Antihypertensive and Anti-Obesity Effects of Eucommia Leaf Extract between Rodents and Humans
    Sansei Nishibe, Hirotaka Oikawa, Kumiko Mitsui-Saitoh, Junichi Sakai, Wenping Zhang, Takahiko Fujikawa · 2023 · Molecules
  32. Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages – A Follow-up Analysis of Health Insurance Data from Germany
    Martin Busch, Thomas Lehmann, Günter Wolf, Christian Günster, Ulrich Müller, Nicolle Muller · 2020 · Experimental and Clinical Endocrinology & Diabetes
  33. The influence of insulin and incretin-based therapies on renal tubular transport
    Erica Rosati, Gianfranco Di Giuseppe, Teresa Mezza, Pietro Manuel Ferraro · 2024 · Journal of Nephrology
  34. Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review
    Nandan Joshi, Kanwal Baloch, Shah Rukh, Abdul Moiz Khan, Fnu Muskan, Verkha Kumari, Hasher Khan, Mohd Zeeshan, Ghufran Azam, Saif Khalid et al. · 2024 · Annals of Medicine and Surgery
  35. Gut Hormones in Heart Failure
    Tania Deis, Jens Peter Goetze, Caroline Kistorp, Finn Gustafsson · 2024 · Circulation Heart Failure
  36. Addressing Renal Sodium Avidity in Chronic Heart Failure: There Is Always More than One Way to Skin a Cat
    Marco Montomoli, Miguel González, José Luis Górriz, María Jesús Puchades Montesa, Gonzalo Nuñez Marín, Ma Soledad Lecueder · 2025 · Cardiorenal Medicine
  37. The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial
    Søren Gullaksen, Liv Vernstrøm, Steffen Skovgaard Sørensen, Steffen Ringgaard, Christoffer Laustsen, Henrik Birn, Kristian Løkke Funck, Per Løgstrup Poulsen, Esben Laugesen · 2024 · Journal of Diabetes and its Complications
  38. Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines
    Larry A. Weinrauch, Alissa R. Segal, George P Bayliss, Jiankang Liu, Eric Wisniewski, John A. D’Elia · 2017 · Clinical Kidney Journal
  39. Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight
    Masami Tanaka, Hiroshi Itoh · 2025 · Hypertension Research
  40. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants
    Tanja Vukajlovic, Clara Odilia Sailer, Ali Asmar, Boye Lagerbon Jensen, D. Vogt, Mirjam Christ‐Crain, Bettina Felicitas Winzeler · 2022 · The Journal of Clinical Endocrinology & Metabolism
  41. Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1
    Hisham A. Nematalla, Mona Elharoun, Eman Sheta, Samar R. Saleh, Marianne Basta, Ali Hussein Eid, Ahmed Fawzy EL‐Yazbi · 2025 · Biochemical Pharmacology
  42. The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
    Dhir Gala, Fady Botros, Amgad N. Makaryus · 2025 · Reviews in Cardiovascular Medicine
  43. Диуретическое действие инкретинмиметиков у крыс
    T. A. Karavashkina, E. V. Balbotkina, Юлия Алексеевна Савина, Анна Вячеславовна Кутина · 2020 · Экспериментальная и клиническая фармакология
  44. Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
    Qianyi Li, Chunxuan Wu, Shiqun Sun, Ling-Chao Yang, Yanyan Li, Yixin Niu, Li Zhang, Wei Li, Ying Yu · 2024 · Journal of Diabetes
  45. Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Ashish Sarraju, Sun H. Kim, Joshua W. Knowles · 2016 · Current Atherosclerosis Reports
  46. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action
    Marie Helene Schernthaner-Reiter, Guntram Schernthaner · 2016 · Expert Review of Endocrinology & Metabolism
  47. Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors
    Chi‐Jung Chung, Hsin‐Ying Lu, Mu‐Chi Chung, Laing‐You Wu, Chieh Huo, Li‐Kuo Kuo, Chun‐Chieh Liu, Chih‐Pin Chuu · 2025 · Journal of the American Heart Association
  48. Incretin-based therapies for the failing heart
    John R. Ussher, Jonathan Edward Campbell · 2016 · Cardiovascular Endocrinology
  49. Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?
    HARPREET SINGH BAJAJ, Bernard Zinman · 2016 · Canadian Journal of Diabetes
  50. Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Side Effects
    Rizal Rizal, Suharjono Suharjono · 2021 · Pharmaceutical Journal of Indonesia
  51. Hemodynamic effects by glucagon-like peptide-1 receptor analogues
    Peter M. Nilsson · 2017 · Journal of Hypertension
  52. A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulation
    Nora Hassan J. Alharbi · 2024 · Preprints.org
  53. Obesity alters global response to ischemia and GLP-1 agonism
    Daniel Sassoon · 2016 · ProQuest Demo Repository
  54. The role of glucagon like peptide - 1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus
    Vaishnavi Menon · 2019 · Endocrine Abstracts
  55. Effect of insulin on natriuretic peptide gene expression in porcine heart
    Dijana Terzic, Nora Elisabeth Zois, Ingrid Hunter, Christina Christoffersen, Peter Plomgaard, Lisbeth H. Olsen, Stine Ringholm, Henriette Pilegaard, Jens Peter Goetze · 2020 · Peptides
  56. 14aPS-87 イオンの拡散により相互作用する電位依存性イオンチャネルの協同性(ポスターセッション, 領域 11)
    晶弘 矢野, 邦禎 蛯名 · 2004 · 日本物理学会講演概要集
  57. Effects of Exenatide on Blood Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes
    Yaqin Zhang, Ruofei Chen, Yangyang Jia, Zongwen Shuai, Mingwei Chen · 2021 · Research Square
  58. Bernard Zinman: A Canadian Clinician Scientist Changing the Management of Diabetes
    Daniel J. Drucker · 2022 · Diabetes Care
  59. Glucagon-like peptide-1 stimulates acute secretion of pro-atrial natriuretic peptide from the isolated, perfused pig lung exposed to warm ischemia
    Emilie Balk-Møller, M. Hebsgaard, Nikolaj Bang Lilleør, Christian Holdflod Møller, Jens Peter Goetze, Hannelouise Kissow · 2022 · Frontiers in Transplantation
  60. Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
    Satoru Kuriyama, Kei Matsumoto · 2022 · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
  61. Improving kidney protection in patients with type 2 diabetes
    Annemarie B. van der Aart‐van der Beek · 2023
  62. CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS TREATED WITH SGLT2I AND GLP1–RA: SYSTEMATIC REVIEW AND META–ANALYSIS
    G. Marino, Alessandro Alonzo, Alessandro Aiello, Stefania Angela Di Fusco, Stefano Aquilani, Furio Colivicchi · 2025 · European Heart Journal Supplements
  63. Additional file 1 of Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
    Ferdinand, Keith C., Dunn, Julia, Nicolay, Claudia, Flora Sam, Emily K. Blue, Wang, Hui · 2023 · Figshare
  64. Additional file 1 of Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
    Natali, Andrea, Lorenzo Nesti, Tricò, Domenico, Ele Ferrannini · 2021 · Figshare
  65. Additional file 1 of Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
    Yamada, Takayuki, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Miyashita, Hirotaka, Mikami, Takahisa, Ueyama, Hiroki, Fujisaki, Tomohiro, Saigusa, Yusuke, Yamaji, Takahiro et al. · 2021 · Figshare
  66. Anti-obesity drugs: comprehensive review and emerging therapies
    Pranav Marne, Swapnil D. Patil, Amisha Vora, Mohd Usman MohdSiddique, Yatin U. Gadkari, Prashant Kurkute · 2026 · Endocrine
  67. Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
    Carolina B. Lobato, Jens J. Holst · 2026 · Elsevier eBooks